Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully. (more…)
Author: Willem van Lawick
-
Pronota presents foundation of Next Generation Sequencing application to identify and quantify proteins.
Ghent, Belgium, 19th May 2010 – Pronota, the Belgian developer of protein biomarker diagnostics, announced today its successful proof of concept of a novel, diagnostic platform. The company reports the first Next Generation Sequencing (NGS) application to identify and quantify proteins. (more…)
-
Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million
Ghent, Belgium, 17th May 2010 – Pronota NV today announced that it has raised an additional EUR 1.5 million in the final close of its Series B financing. The financing has been subscribed by MedSciences Capital, the venture capital arm of Kempen & Co, which is a specialized Dutch merchant bank. Pronota has raised a total of EUR 7.9 million in its Series B round, which has been subscribed by premier life sciences investors such as Gimv, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management Inc., Baekeland Fund and MedSciences Capital. Pronota is using the proceeds of the Series B financing to push forward its diagnostic development programs in the cardio-renal area, pre-eclampsia, sepsis, and ovarian cancer. (more…)
-
Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality – FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants.
ATIR™ continues to show excellent clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. The two year follow up data from the phase I/II study show no Transplant Related Mortality (TRM) in a group of 10 high risk leukemia patients who received an efficacious dose of ATIR™. The overall survival of this group after two years is 70%. These results compare favorably to outcomes of bone marrow transplantations from a full matching donor. (more…)
-
Mucosis appoints Dr. Roberto Grimandi as chief medical officer
Dutch vaccine development company MUCOSIS B.V. announced today that Dr. Roberto Grimaldi, MD was appointed Chief Medical Officer at Mucosis. Dr. Grimaldi is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience. As an expert on vaccine development he will lead the Mucosis development programs into clinical trials in the near future. (more…)